...Hwa Jung Sung; Se Ryeon Lee; In Keun Choi; Yong Park; Chul Won Choi; Hyeoung-Joon Kim; Ho-Young Yhim; Byung Soo Kim Aim: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose...

...Yuanyuan Li; Zhikui Deng; Jiabin Zhu; Banhe Ding; Yuye Shi; Yufeng Li Background: The therapeutic response of chronic myelogenous leukemia in myeloid blast crisis (CML-MBC) is very poor. Aim: To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML...

...Mitsutaka Nishimoto; Hirohisa Nakamae; Ki-Ryang Koh; Saori Kosaka; Kana Matsumoto; Kunihiko Morita; Hideo Koh; Takahiko Nakane; Masahiko Ohsawa; Masayuki Hino A 22-year-old male with Ph-positive chronic myelogenous leukemia (CML) was started on treatment with imatinib. After 12 months of therapy...

... the incidence and the prognostic role of a very early standard complete cytogenetic response (CCyR) or all Ph– metaphases (MET–, when <20 cells were evaluable). Methods: We revised 182 chronic phase chronic myelogenous leukemia patients treated with frontline imatinib (IM) at two institutions from June 2002...

... report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time...

...), mutations of the BCR-ABL tyrosine kinase domain (TKD) and BCR-ABL splice variants may cause resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoid leukemia (ALL). Methods: Karyotyping and BCR-ABL TKD...

...Min Huang; Zhenping Hu; Wei Chang; Dongmei Ou; Jianfeng Zhou; Yicheng Zhang The activation of ABL tyrosine kinase in BCR/ABL-positive chronic myelogenous leukemia (CML) leads to a diversity of biological changes related to the pathogenesis of the disease. In CML patients, we determined...

...Hege K. Vefring; Franz X.E. Gruber; Line Wee; Randi Hovland; Henrik Hjorth-Hansen; Tobias Gedde Dahl; Peter Meyer The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have...

...Lillian Y. F. Hsu; Peter Papenhausen; Michael L. Greenberg; Kurt Hirschhorn A female patient with chronic myelogenous leukemia was found to have 47, XX, + D in 100% of her bone marrow cells. There was no Ph 1 chromosome. Fluorescent staining showed that the extra D group chromosome was most likely...

...Joseph Grinblat; Zipora Mammon; Zigmund Lewitus; Henry Joshua An unusual case of chronic myelogenous leukemia (CML) is reported, which was characterized by leukocytosis without a shift to the left, elevated leukocyte alkaline phosphatase, positive indirect Coombs’ test, anemia and thrombocytosis...

...J. Whang-Peng; S. Broder; E. Lee; R.C. Young Several unusual cytogenetic changes have occurred during the evolution of chronic myelogenous leukemia in a 32-year-old white male with this disease for 8 years. The first appearance of a hypodiploid cell line containing a di-centric marker occurred 2...

...R. Sasaki; F. Takaku; S. Sakamoto; Y. Kanoh High terminal deoxynucleotidyl transferase activities were found in blast cells having B cell markers in 3 patients suffering from chronic myelogenous leukemia. The blast cells from these patients were lymphoblastic in appearance. Two of these cases were...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Chronic myelogenous leukemia...

.... At the age of 84, chronic myelogenous leukemia (CML) developed. Cytogenetic studies revealed incomplete trisomy of the long arm of chromosome No. 1 as the only karyotypic abnormality. No Philadelphia chromosome was detected. The significance of trisomy lq as an isolated cytogenetic abnormality in CML...

...J.D. Lutton; J.W. Chiao; J.L. Ascensao; M. Atamer; Z. Arlin; R.D. Levere Bone marrow and peripheral blood cells from a patient with chronic myelogenous leukemia in erythroblastic transformation were studied by flow cytometry and for hemopoietic colony growth. Results demonstrated that this disorder...

...Elizabeth T. Velasquez; Ram S. Verma; M. Krishnamurthy; Harvey Dosik We present a case with the clinical and pathological impression of Ph 1 -positive chronic myelogenous leukemia in extramedullary blast crisis involving lymph nodes as demonstrated by morphological and cytogenetic studies...

...%) showed Ph suppression which was persistent in 13 for > 21 months. Survival was better in patients obtaining remission with IFN- α . Recombinant gamma interferon (IFN-γ) was also active in chronic myelogenous leukemia. Therapy with combined IFN- α + IFN-γ has been initiated. Compared to the expected...

...W.M. Mars; C.M. Stellrecht; J.W. White; G.F. Saunders Differential screening of a CML-derived cDNA library was used to isolate a cDNA clone representing an abundant mRNA in leukocytes of chronic phase, chronic myelogenous leukemia (CML) patients. This myeloid-related sequence (mrs) comprises...

.... Chronic myelogenous leukemia Isochromosome i(X)(q13) Myelofibrosis 26 06 1988 18 10 1988 24 2 2009 Acta Haemat 1989;81:152-154 © 1989S. Karger AG, Basel 0001-5792/89/0813-0152 $ 2.75/0 Isodicentric X Chromosome in Myeloproliferative Disorders Paola Temperani, Patrizia Zucchini...

... developed latex immunoassay using monoclonal antibodies which do not cross-react with fibrinogen. 5 patients with chronic myelogenous leukemia (CML) had highly elevated FDP levels with normal levels of D dimer. Plasma samples from such patients with CML were treated with various concentrations of thrombin...